IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 1.916 SEK -1.24% Market Closed
Market Cap: 162.6m SEK

Gross Margin
IRLAB Therapeutics AB

-35.8%
Current
-441%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-35.8%
=
Gross Profit
-30.6m
/
Revenue
85.6m

Gross Margin Across Competitors

No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
162.7m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
9.011 SEK
Undervaluation 79%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-35.8%
=
Gross Profit
-30.6m
/
Revenue
85.6m
What is the Gross Margin of IRLAB Therapeutics AB?

Based on IRLAB Therapeutics AB's most recent financial statements, the company has Gross Margin of -35.8%.

Back to Top